Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Asset Writedowns and Impairment (2023 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 2 years of Asset Writedowns and Impairment data on record, last reported at $1.2 million in Q1 2025.

  • For Q1 2025, Asset Writedowns and Impairment changed N/A year-over-year to $1.2 million; the TTM value through Sep 2025 reached $1.2 million, changed N/A, while the annual FY2023 figure was $5.0 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached $1.2 million in Q1 2025 per ZNTL's latest filing, down from $5.0 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $5.0 million in Q1 2023 and bottomed at $1.2 million in Q1 2025.